Guardant Health (GH) traded higher on Wednesday, May 6, 2026, as the market positioned ahead of the company’s first-quarter 2026 earnings report scheduled for after the close on Thursday, May 7, 2026. With the print imminent, the move looks driven more by pre-earnings positioning and sentiment than a single same-day headline.

In the days and weeks leading into earnings, Guardant has put out several developments that can buoy expectations around demand and longer-term monetization. On April 30, 2026, Guardant announced a multi-year strategic collaboration with Nuvalent focused on developing companion diagnostics and supporting potential commercialization using the Guardant Infinity platform. Separately, on March 10, 2026, Guardant said its Shield blood-based colorectal cancer screening test became accessible through Quest Diagnostics’ national test ordering and collection network, which investors may view as a distribution tailwind for screening volumes.

Thursday’s earnings call will be a key checkpoint for Shield screening revenue and test volumes, oncology testing trends, and biopharma/data contributions. Investors will also be listening for commentary on operating expenses, cash usage, and any updates to 2026 outlook ranges, with particular sensitivity to how quickly screening ramps relative to expectations.